Related Experiment Video
Updated: Jul 6, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor
Karissa Britten1, Nicholas McAndrew
1Division of Hematology/Oncology; University of California, Los Angeles, CA, USA.
Purpose Of Review:
In recent years, there has been a flurry of activity in the human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer space. New, powerful drugs like trastuzumab deruxtecan have challenged our fundamental definition of what HER2 expression means as a predictive biomarker.
Recent Findings:
Recent approvals of multiple agents in the second line-metastatic setting have given patients access to a variety of new agents, but also raise questions with regard to optimal sequencing.
Summary:
This review will explore current issues with HER2 testing, recently approved drugs in the HER2+ and HER2 low spaces, as well as novel agents/combinations on the horizon.
Insights
New drugs for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer offer more treatment options but raise questions about optimal drug sequencing. This review covers HER2 testing, new approvals, and future therapies.
Area of Science:
- Oncology
- Medical Science
Background:
- The landscape of HER2-positive metastatic breast cancer treatment is rapidly evolving.
- Recent drug approvals have expanded therapeutic options for patients in the second-line metastatic setting.
Approach:
- This review synthesizes current data on human epidermal growth factor receptor 2 (HER2) testing methodologies.
- It examines recently approved agents for HER2-positive and HER2-low metastatic breast cancer.
- The review also discusses emerging novel therapeutic agents and combinations.
Key Points:
- Trastuzumab deruxtecan exemplifies new therapies challenging the predictive role of HER2 expression.
- Optimal sequencing of newly approved agents in the metastatic setting remains an open question.
- Advances in HER2 testing are crucial for guiding treatment decisions.
Conclusions:
- The evolving treatment paradigm for HER2-positive and HER2-low metastatic breast cancer necessitates a re-evaluation of diagnostic and therapeutic strategies.
- Further research is needed to establish optimal sequencing of novel agents to maximize patient outcomes.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
